Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:45 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
NCT02153905 · National Cancer Institute (NCI) · PHASE1/PHASE2 · terminated · last registry update 2019-06-17 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow, insufficient accrual.” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL2RA in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-06-06Results posted on the registry: Masonic Cancer Center, University of Minnesota, allogeneic large multivalent immunogen breast cancer vaccine + aldesleukin (NCT00784524)
- 2019-06-06Also stopped (terminated): Masonic Cancer Center, University of Minnesota, allogeneic large multivalent immunogen breast cancer vaccine + aldesleukin (NCT00784524)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision